Anemia diagnosis and therapy in malignant diseases: implementation of guidelines-a representative study.

"Declarations Ethics approvalAn opinion has been obtained from the Ethics Committee of Rhineland-Palatinate, Mainz, Germany, in accordance with the guidelines and recommendations for ensuring Good Epidemiological Practice (GEP) [27]. Due to the nature of the study, no additional opinions from ethics committees were required. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsHartmut Link: funding Pharmacosmos, institutional, research grant to German Cancer Society; Teva, research grant; financial interests, speaker and consultant honoraria Pharmacosmos, Teva. Markus Detzner, Laura Holtmann, and Markus Kerkmann have no interests to declare that are relevant to the content of this article. DisclaimerThe funding source did not have any access to the data and was not involved in data analysis or manuscript writing. Standard of reportingThe guidelines for Observational Studies in Epidemiology (STROBE) were taken into account as far as applicable [47]. Competing interests Hartmut Link: funding Pharmacosmos, institutional, research grant to German Cancer Society; Teva, research grant; financial interests, speaker and consultant honoraria Pharmacosmos, Teva. Markus Detzner, Laura Holtmann, and Markus Kerkmann have no interests to declare that are relevant to the content of this article."

"Funding Working Groups Supportive Care (AGSMO) and Medical Oncology (AIO) of the German Cancer Society (DKG), study number AIO-SUP-0121. The study was funded by a research grant from Pharmacosmos to the AIO-Studien-gGmbH of the German Cancer Society."

"Trial registration ClinicalTrials.gov, NCT05190263, date: 2022–01-13."